German pharmaceutical and chemical company Bayer AG related Thu. it’ll appeal a decision by the U.K.’s healthcare cost regulator not to endorse the company’s Nexavar for liver cancer treatment.

The U.K.’s countrywide Institute for Health and Clinical Excellence, or NICE, claimed it declined to recommend that the in public bankrolled health system use Nexavar to treat complicated liver cancer, claiming it isn’t inexpensive. I do not know the usefulness of this drug, but evidently it did not meet the profit margin standards.

NICE is the agency that decides whether new drugs are inexpensive for the nation’s Health Service in England and Wales. Such appraisals, which are made before NICE issues last steering to the NHS, are closely studied by other governments and health insurers. Is this what is in store for the United States?

This is the second time NICE has declined to recommend the drug, which is understood generically as sorafenib and marketed with Onyx Pharmaceuticals Inc., for cancer of the liver treatment. After a preliminary refusal in May, Bayer submitted a new patient access scheme whereby the company offered to pay for each 4th pack of Nexavar.

Cancer Prevention